A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 9, 2005, Pages 1297-1304

  Mehra, Mandeep R ^a,g,h   Zucker, Mark J ^b   Wagoner, Lynne ^c   Michler, Robert ^d   Boehmer, John ^e   Kovarik, John ^f   Vasquez, Arthur ^f  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Cardiomyopathy and Heart Transplant Center   (United States)

^h JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; PLACEBO;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; FEMALE; FEVER; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; UNITED STATES;

EID: 24344508163     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.09.010     Document Type: Article

References (29)

1. S. Itescu, T.C.M. Tung, E.M. Burke An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients Lancet 352 1998 263 270
2. T.M. Schneider, J.W. Kupiec-Weglinski, E. Towpik Development of suppressor lymphocytes during acute rejection of rat cardiac allografts and preservation of suppression by anti-IL-2-receptor monoclonal antibody Transplantation 42 1986 191 196
3. T.A. Waldmann The IL-2/IL-2 receptor system A target for rational immune intervention Immunol Today 14 1993 264 270
4. A.B. Cosimi Future of monoclonal antibodies in solid organ transplantation Dig Dis Sci 40 1995 65 72
5. P.L. Amlot, E. Rawlings, O.N. Fernando Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation Transplantation 60 1995 748 756
6. B.D. Kahan, P.R. Rajagopalan, M. Hall United States Simulect Renal Study Group Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody Transplantation 67 1999 276 284
7. B. Nashan, R. Moore, P. Amlot, A.G. Schmidt, K. Abeywickrama, J.P. Soulilloo CHIB 201 International Study Group Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients Lancet 350 1997 1193 1198
8. D. Adu, P. Cockwell, N.J. Ives, J. Shaw, K. Wheatley Interleukin-2 receptor monoclonal antibodies in renal transplantation Meta-analysis of randomised trials BMJ 326 2003 789 791
9. C. Ponticelli, A. Yussim, V. Cambi Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine Transplant Proc 33 2001 1009 1010
10. J.G. Lawen, E.A. Davies, G. Mourad Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation Transplantation 75 2003 37 43
11. J.E. Hartle, J.E. Bisordi, S. Chao, M.J. Freeland, J.C. West The addition of basiliximab to CellCept, Neoral and steroids resulted in a significant reduction in acute renal allograft rejection [abstract] Transplantation 69 S 2000 S159
12. J.M. Kovarik, B.D. Kahan, P.R. Rajagopalan Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation Transplantation 68 1999 1288 1294
13. 4 (basilixmab) versus OKT3 in heart transplantation [abstract] J Heart Lung Transplant 22 2003 S141
14. Delgado D, Cusimano RJ, Feindel C, et al. Simulect (basiliximab) improves renal function in high risk patients undergoing heart transplantation [abstract]. Available at: http://www.ccs.ca/society/congress2001/abstracts/abs/ a413.htm. Accessed October 7, 2004.
15. A. Beniaminovitz, S. Itescu, K. Lietz Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody N Engl J Med 342 2000 613 619
16. N.M. Edwards, H.A. Rajasinghe, R. John, J.M. Chen, S. Itescu, D.M. Mancini Cardiac transplantation in over 1000 patients A single institution experience from Columbia University J.M. Cecka P.I. Terasaki Clinical transplants 1999 UCLA Immunogenetics Center Los Angeles, CA 249 261
17. K. Lietz, R. John, A. Beniaminovitz Interleukin-2 receptor blockade in cardiac transplantation influence of HLA-DR locus incompatibility on treatment efficacy Transplantation 75 2003 781 787
18. C.C. Baan, A.H.M.M. Balk, I.C. van Riemsdijk Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation Transplantation 75 2003 1704 1710
19. R.L. Kirkman, L.V. Barrett, G.N. Gaulton, V.E. Kelley, A. Ythier, T.B. Strom Administration of an anti-interleukin-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice J Exp Med 162 1985 358 362
20. J.W. Kupiec-Weglinski, T. Diamantstein, N.L. Tilney, T.B. Strom Therapy with monoclonal antibody to interleukin-2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats Proc Natl Acad Sci USA 83 1986 2624 2627
21. G. Rabago, N. Manito, L. Almenar Induction therapy with two doses of daclizumab in heart transplantation: a prospective, multi centric clinical study. Interim analysis [abstract] J Heart Lung Transplant 22 S1 2003 S123
22. MedWatch. 2003 safety alert: Zenapax (daclizumab). Available at: http://www.fda.gov/medwatch/SAFETY/2003/zenapax.htm. Accessed October 7, 2004.
23. S. Fischer, M. Strüber, B. Gohrbandt, A. Simon, C. Bara, A. Haverich Anti-CD25 antibody (basilixmab) therapy is not superior to anti-thymocyte globuline (ATG) for immunosuppression induction following heart transplantation [abstract] J Heart Lung Transplant 22 2003 S122
24. Lambert J.L. Rodriguez, Leiro M.G. Cresp, J. Segovia Final results of the study of safety and tolerability of Simulect (basiliximab) versus OKT3 in heart transplantation [abstract] J Heart Lung Transplant 22 2004 S122
25. A.E. Vriesendorp, P.B. Rosenberg, M.H. Drazner Induction with basiliximab preserves renal function following cardiac transplantation [abstract] Am J Transplant 1 S1 2001 432
26. M. Cantarovich, P. Metrakos, N. Giannetti, R. Cecere, J. Barkun, J. Tchervenkov Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction Transplantation 73 2002 1169 1172
27. J.M. Kovarik Basiliximab pharmacokinetics and immunodynamics in clinical transplantation Graft 2 1999 193 195
28. H.J. Eisen, E.M. Tuzcu, R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847 858
29. S. Vitko, H. Tedesco, J. Eris Everolimus with optimized cyclosporine dosing in renal transplant recipients 6-month safety and efficacy results of two randomized studies Am J Transplant 4 2004 626 635